Regulatory News:
ERYTECH Pharma (Paris:ERYP) (Euronext Paris: FR0011471135 - ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announces the granting of two key patents for its core product ERY-ASP.
ERYTECH recently received notice of allowance from the European Patent Office of a key patent covering its lead product ERY-ASP for the treatment of pancreas cancer. The patent entitled “Medicament for the Treatment of Cancer of the Pancreas” was filed in late 2007 and has in the meantime been granted in Australia, Israel and Singapore. For reminder, ERYTECH has received at the beginning of May the green light from the French Medicines Agency (ANSM) for a Phase II study with ERY-ASP in pancreas cancer. The study is expected to enroll first patients in the coming months.
ERYTECH’s core process patent was also recently granted in India. This patent entitled “Lysis/Resealing Process for Preparing Erythrocytes” is the core protection of the technology platform and products developed by ERYTECH. With this additional grant ERYTECH proprietary technology benefits from a broad coverage internationally. The patent application that was filed in 2004 was already granted in Europe, USA, Japan, China, Hong-Kong, Australia and South-Korea.
“These additional patent grants further strengthen ERYTECH’s intellectual property position and confirm the uniqueness of our encapsulation technology for the development of safer and longer acting drugs using red blood cells as a vehicle”, comments Gil Beyen, CEO of ERYTECH.
ERYTECH participates at the following events:
- Jefferies Global Healthcare Conference, June 2-5 in New York
- Village des Actionnaires, June 12 in Lyon
- French Life Science Days, June 25-26 in New York
About pancreas cancer:
Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. Every year about 45,000 patients are diagnosed with pancreatic cancer in the US, and about 80,000 in Europe. According to the American Cancer Society, for all stages of pancreatic cancer combined, the one-year relative survival rate is 20%, and the five-year rate is 6% to 10%. Pancreatic cancer is currently the fourth most common cause of cancer death in the EU for men and women. Death rates from the disease are predicted to rise from 7.8 in 2009 to 8.0 in 2013 per 100,000 among men, and from 5.3 to 5.5 per 100,000 among women in same period. In fact, the pancreas is the only major cancer site for which no improvements in mortality rates is predicated1.
About ERYTECH and ERY-ASP/GRASPA®: www.erytech.com
ERYTECH is a French biopharmaceutical company providing new prospects for cancer patients, particularly those with acute leukemia and selected solid tumors. The company is also developing other indications in solid tumors and certain orphan indications outside oncology.
ERYTECH is listed on Euronext regulated market in Paris. (ISIN code: FR0011471135, ticker: ERYP) and is part of the CAC All Shares, CAC Healthcare, CAC Pharma & Bio, CAC Small, CAC Mid&Small, CAC All Tradable and Next Biotech indexes. ERYTECH shares are eligible to PEA-PME (French share savings plan for SMEs).
For more information about the Company, please read About ERYTECH and ERY-ASP/GRASPA
Forward-looking information
This document may contain forward-looking statements, forecasts and estimates (“Statements”) with respect to the financial situation, the results of operations, the strategy, the project and to the anticipated future performance of ERYTECH Pharma. Documents filed by ERYTECH Pharma with the French Autorité des Marchés Financiers (www.amf-france.org), also available on our website (www.erytech.com) describe such risks and uncertainties for which ERYTECH Pharma makes no representations or warranty as to their accuracy or fairness. Furthermore, such Statements only speak as of the date of the publication of this document. ERYTECH disclaims any obligation to update any such Statements except to the extent required by French law.
For more information about Forward-looking information, please read Forward-looking information
1 Malvezzi M et al., Annals of Oncology 2013, 1-9
